Source comparison
Comparison: Sermorelin vs Exogenous GH vs Other Secretagogues for IGF-1 Research
Researchers evaluating IGF-1 modulation have multiple tools available. Sermorelin, exogenous recombinant human growth hormone (rhGH), and GH secretagogues like ipamorelin or MK-677. The choice depends on the research objective, the tolerance for adverse events
This comparison does not assign a generated winner or score.
- Researchers evaluating IGF-1 modulation have multiple tools available. Sermorelin, exogenous recombinant human growth hormone (rhGH), and GH secretagogues like ipamorelin or MK-677. The choice depends on the research objective, the tolerance for adverse events, and whether the goal is to mimic physiological GH pulsatility or achieve sustained supraphysiological IGF-1 levels.
- Sermorelin (200–300 mcg/day)
- GHRH analogue → stimulates endogenous GH → hepatic IGF-1 synthesis
- 50–150% above baseline at 12–24 weeks
- Yes. Maintains circadian rhythm and negative feedback
- Requires intact pituitary function; age-dependent response attenuation
- Best option for research modelling physiological GH–IGF-1 dynamics without overriding endogenous regulation
- Exogenous rhGH (2–4 IU/day)
- Direct GH administration → bypasses pituitary → hepatic IGF-1 synthesis
- 200–400% above baseline within 4–8 weeks
- No. Suppresses endogenous pulsatility entirely
- Sustained supraphysiological GH levels; higher adverse event rate (oedema, joint pain, insulin resistance)
- Produces fastest and highest IGF-1 elevation but least physiological; appropriate for deficiency states, not for modelling healthy ageing or metabolism
- Ipamorelin (200–300 mcg/day)
- Ghrelin mimetic → GH secretagogue receptor agonist → endogenous GH release
- 30–80% above baseline at 12 weeks
- Yes. Selective GH release without cortisol or prolactin co-secretion
- Lower peak GH response than sermorelin; requires higher dosing frequency
- Cleaner secretagogue profile than GHRP-6 or GHRP-2 but weaker IGF-1 response than sermorelin
- MK-677 (25 mg/day oral)
- Ghrelin receptor agonist → sustained GH elevation → IGF-1 synthesis
- 60–120% above baseline at 8–12 weeks
- Partially. Increases GH AUC but blunts pulsatility amplitude
- Oral convenience but sustained GH elevation causes appetite stimulation and insulin resistance in some subjects
- Strongest oral option for IGF-1 research; useful when injection compliance is a barrier
- For research contexts where the objective is to mimic healthy endogenous GH–IGF-1 dynamics. Such as ageing studies, body recomposition research, or metabolic health models. Sermorelin remains the gold standard because it preserves pulsatility and negative feedback. For research requiring maximal IGF-1 elevation regardless of physiological pattern (e.g., wound healing models, severe catabolic states), exogenous GH produces faster and higher response but at the cost of disrupting the endogenous axis.